Of note, the ratio of secondary to de novo metastatic EGFR+ NSCLC, approximately 1:4 in our study (Table 1), itself is not a purely biological characteristic either, but also influenced by the efficacy of lung cancer detection strategies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.